Beyond the Clinic Walls: Fostering Well-Being in a Client with Schizoaffective Disorder (SAD) Through Home Care and Clozapine Therapy - A Case Report
DOI:
https://doi.org/10.26463/rjns.14_1_1Keywords:
Schizoaffective disorder, Clozapine therapy, Home careAbstract
Schizoaffective disorder (SAD) is a chronic, severe and disabling illness associated with concurrent presentation of symptoms of schizophrenia and affective disorders. The mainstay of treatment is a combination of antipsychotic medications, and depending on the subtype of schizoaffective disorder, either mood stabilizers or antidepressants are given. Clozapine is a second-generation antipsychotic used in the treatment of SAD. Clozapine-induced agranulocytosis has the highest risk of occurrence during the first few months of treatment. Other common side effects are sialorrhea, constipation, dehydration, and hyperglycaemia. Adequately managing side effects can improve adherence and quality of life. Physical health should be monitored at each clinical review, particularly in the first few months of treatment, to reduce the occurrence of serious, sometimes fatal adverse reactions. Many clients find clozapine to help with their psychosis, but they often need to balance the positive effect of psychosis with some of the side effects that clozapine can cause.
References
1. Oloyede E, Dunnett D, Taylor D, Clark I, MacCabe JH, Whiskey E, et al. The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia. BMC Psychiatry 2023;23(1):413.
2. Souto DR, Espinosa JP, Vieta E, Hernández AB. Clozapine in patients with schizoaffective disorder: A systematic review. Revista de Psiquiatría y Salud Mental (English Edition) 2021;14(3):148-56.
3. Srour A, Eltorki Y, Malik H, Alabdulla MA, Hassan MH, Al Subaiey MA, et al. Patients' and primary carers' views on clozapine treatment for schizophrenia: A cross-sectional study in Qatar. Saudi Pharm J 2023;31(2):214-21.
4. Kar N, Barreto S, Chandavarkar R. Clozapine monitoring in clinical practice: beyond the mandatory requirement. Clin Psychopharmacol Neurosci 2016;14(4):323
5. Mizuno K, Mizuno E, Suekane A, Shiratsuchi T. Efficacy of clozapine for long‐stay patients with treatment‐resistant schizophrenia: 4‐year observational study. Neuropsychopharmacol Rep 2022;42(2):183-90.
6. Taşdelen R, Kaya H, Üçok A. Side effects of clozapine treatment in patients with schizophrenia and schizoaffective disorder and their role in the discontinuation of treatment. Bosphorus Med J 2023;10(1):32-9.
7. Paudel S, Brown H, Freudenreich O. The neurobiology of schizoaffective disorder. Psychiatric Annals 2020;50(5):190-4.
